Structure Therapeutic's drug has the same mechanism of action as Ozempic (GLP-1 receptor agonist). We all know what a horror show that is. One has to wonder how much of the weight loss is due to diarrhea and vomiting.

Quote:

---

The use of glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and weight loss management – including semaglutide (Ozempic/Rybelsus/Wegovy, Novo Nordisk) – have previously been linked to adverse GI events such as abdominal pain, constipation, diarrhea, nausea and vomiting. Following post-marketing adverse reaction reports of patients who developed ileus while prescribed Ozempic, the FDA has opted to revise the drug label to alert prescribers of this potential risk.
https://www.healio.com/news/gastroenterology/...cemia-risk

---